Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus

被引:173
作者
Fredericksen, BL
Wei, BL
Yao, J
Luo, TC
Garcia, JV
机构
[1] Univ Texas, SW Med Ctr, Dept Internal Med, Div Infect Dis, Dallas, TX 75390 USA
[2] Genet Therapy Inc, Gaithersburg, MD 20878 USA
关键词
D O I
10.1128/JVI.76.22.11440-11446.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Productive entry of human immunodeficiency virus type 1 (HIV-1) into a host cell is believed to proceed via fusion of the viral envelope with the host cell's plasma membrane. Interestingly, the majority of HIV-1 particles that bind to the cell surface are taken up by the host cell via endocytosis; however, this mode of internalization generally does not result in infection. Presumably, virus particles remain trapped in the endocytic pathway and are eventually. degraded. Here, we demonstrate that treatment of cells with various pharmacological agents known to elevate the pH of endosomes and lysosomes allows HIV-1 to efficiently enter and infect the host cell. Pretreatment of cells with bafilomycin Al results in up to a 50-fold increase in the infectivity of HIV-1(SF2). Similarly, pretreatment of target cells with amantadine, concanamycin A, concanamycin B, chloroquine, and ammonium chloride resulted in increases in HIV-1 infectivity ranging between 2- and 15-fold. Analysis of receptor and coreceptor expression, HTV-long terminal repeat (LTR) transactivation, and transduction with amphotropic-pseudotyped murine leukemia virus (MLV)-based vectors suggests that the increase in infectivity is not artifactual. The increased infectivity under these conditions appears to be due to the ability of HIV-1 and MLV particles to enter via the endocytic pathway when spared from degradation in the late endosomes and lysosomes. These results could have significant implications for the administration of current and future lysosmotropic agents to patients with, HIV disease.
引用
收藏
页码:11440 / 11446
页数:7
相关论文
共 49 条
[1]   CLINICAL PHARMACOKINETICS OF AMANTADINE HYDROCHLORIDE [J].
AOKI, FY ;
SITAR, DS .
CLINICAL PHARMACOKINETICS, 1988, 14 (01) :35-51
[2]   Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease [J].
Berger, EA ;
Murphy, PM ;
Farber, JM .
ANNUAL REVIEW OF IMMUNOLOGY, 1999, 17 :657-700
[3]  
Bloland PB, 2000, B WORLD HEALTH ORGAN, V78, P1378
[4]   FUSION MUTANTS OF THE INFLUENZA-VIRUS HEMAGGLUTININ GLYCOPROTEIN [J].
DANIELS, RS ;
DOWNIE, JC ;
HAY, AJ ;
KNOSSOW, M ;
SKEHEL, JJ ;
WANG, ML ;
WILEY, DC .
CELL, 1985, 40 (02) :431-439
[5]   LYSOSOMOTROPIC AGENTS [J].
DEDUVE, C ;
DEBARSY, T ;
POOLE, B ;
TROUET, A ;
TULKENS, P ;
VANHOOF, F .
BIOCHEMICAL PHARMACOLOGY, 1974, 23 (18) :2495-+
[6]   Prevention and early treatment of influenza in healthy adults [J].
Demicheli, V ;
Jefferson, T ;
Rivetti, D ;
Deeks, J .
VACCINE, 2000, 18 (11-12) :957-1030
[7]   Beyond receptor expression: The influence of receptor conformation, density, and affinity in HIV-1 infection [J].
Doms, RW .
VIROLOGY, 2000, 276 (02) :229-237
[8]   INHIBITORY EFFECT OF MODIFIED BAFILOMYCINS AND CONCANAMYCINS ON P-TYPE AND V-TYPE ADENOSINE-TRIPHOSPHATASES [J].
DROSE, S ;
BINDSEIL, KU ;
BOWMAN, EJ ;
SIEBERS, A ;
ZEECK, A ;
ALTENDORF, K .
BIOCHEMISTRY, 1993, 32 (15) :3902-3906
[9]  
Drose S, 1997, J EXP BIOL, V200, P1
[10]   Clinical pharmacokinetics and metabolism of chloroquine - Focus on recent advancements [J].
Ducharme, J ;
Farinotti, R .
CLINICAL PHARMACOKINETICS, 1996, 31 (04) :257-274